Dominik F Draxler Selected Research

Tranexamic Acid (AMCA)

3/2022	Characterisation of Plasma Mitochondrial DNA, MMP-9 and Neutrophil Elastase in Patients Undergoing Coronary Artery Bypass Grafting: Effects of Tranexamic Acid and Postoperative Pneumonia.
4/2021	Tranexamic acid rapidly inhibits fibrinolysis, yet transiently enhances plasmin generation in vivo.
10/2020	Sex-dependent effects of tranexamic acid on blood-brain barrier permeability and the immune response following traumatic brain injury in mice.
12/2019	Tranexamic Acid Influences the Immune Response, but not Bacterial Clearance in a Model of Post-Traumatic Brain Injury Pneumonia.
12/2019	Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis.
1/2019	Tranexamic acid modulates the immune response and reduces postsurgical infection rates.
3/2017	Plasmin: A Modulator of Immune Function.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dominik F Draxler Research Topics

Disease

6	Hemorrhage 03/2022 - 04/2015
3	Stroke (Strokes) 01/2023 - 01/2019
3	Pneumonia (Pneumonitis) 09/2022 - 12/2019
3	Inflammation (Inflammations) 03/2022 - 01/2019
3	Critical Illness (Critically Ill) 01/2022 - 12/2015
3	Traumatic Brain Injuries (Traumatic Brain Injury) 10/2020 - 12/2019
3	Wounds and Injuries (Trauma) 01/2019 - 01/2018
2	Ischemic Stroke 01/2023 - 01/2020
2	Sepsis (Septicemia) 01/2022 - 01/2018
2	Infections 01/2019 - 01/2019
1	Nervous System Diseases (Neurological Disorders) 01/2023
1	Thrombocytopenia (Thrombopenia) 09/2022
1	COVID-19 09/2022
1	Septic Shock (Toxic Shock Syndrome) 01/2022
1	Heart Failure 01/2022
1	Brain Ischemia (Cerebral Ischemia) 01/2020
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2019
1	Thrombotic Microangiopathies 01/2018
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2018
1	Atherosclerosis 01/2018
1	Thrombosis (Thrombus) 04/2015

Drug/Important Bio-Agent (IBA)

7	Tranexamic Acid (AMCA)FDA Link 03/2022 - 03/2017
7	Fibrinolysin FDA Link 04/2021 - 04/2015
4	Antifibrinolytic Agents (Antifibrinolytics)IBA 04/2021 - 03/2017
2	Mitochondrial DNA (mtDNA)IBA 03/2022 - 12/2015
2	PlasminogenIBA 01/2019 - 04/2015
2	FibrinIBA 01/2019 - 04/2015
1	Ionotropic Glutamate ReceptorsIBA 01/2023
1	Proteins (Proteins, Gene)FDA Link 01/2023
1	Protein Isoforms (Isoforms)IBA 01/2023
1	AntibodiesIBA 09/2022
1	Heparin (Liquaemin)FDA LinkGeneric 09/2022
1	Platelet Factor 4IBA 09/2022
1	Leukocyte Elastase (Neutrophil Elastase)IBA 03/2022
1	Peptides (Polypeptides)IBA 01/2022
1	Neprilysin (Neutral Endopeptidase)IBA 01/2022
1	Lysine (L-Lysine)FDA Link 04/2021
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 10/2020
1	Toll-Like Receptor 2IBA 01/2020
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020
1	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2020
1	Interleukin-10 (Interleukin 10)IBA 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	Hemostatics (Antihemorrhagics)IBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2018
1	Aprotinin (Trasylol)FDA Link 03/2017
1	Aminocaproic Acid (6 Aminocaproic Acid)FDA LinkGeneric 03/2017
1	Enzyme Precursors (Zymogens)IBA 04/2015
1	Tissue Plasminogen Activator (Alteplase)FDA Link 04/2015
1	Plasminogen Activators (Plasminogen Activator)IBA 04/2015

Therapy/Procedure

1	Extracorporeal Membrane Oxygenation 09/2022
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 03/2022